Compare Novavax Inc (NVAX) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Suncor Energy Inc. — how do they compare? Novavax Inc trades at $11.11 (market cap $1.82B), while Suncor Energy Inc. trades at $70.57 (market cap $82.76B). The key difference: Suncor Energy Inc. is far larger — about 45.5× Novavax Inc's market cap, and Suncor Energy Inc. pays a 2.39% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Suncor Energy Inc. for 57 Days on average.
| NVAX | SU | |
|---|---|---|
Market Cap | $1.82B | $82.76B |
Volume | 6,198,505 | 3,832,959 |
Sector | Health | Energy |
52-Week High | $12.56 | $71.87 |
52-Week Low | $6.22 | $38.17 |
Typical Hold Time | 59 Days | 57 Days |
Enterprise Value | $1.39B | $89.29B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Suncor Energy (SU) trades at $68.14, down 0.12% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a P/E of 12.98, ROE of 19.25%, and consistent earnings beats in recent quarters. Recent news highlights strategic asset sales and leadership transitions, while analyst consensus remains strongly positive with 74% buy ratings. Cash flow trends show operational strength with $12.78B from operations in 2025.
SU presents a compelling value opportunity with attractive valuation metrics and robust shareholder returns through dividends and buybacks. Key risks include commodity price volatility and operational challenges from weather disruptions. The company's integrated model and international revenue diversification provide stability, though investors should monitor execution under new leadership and global energy market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
